TY  - JOUR
AU  - Jost, Stefanie T.
AU  - Visser-Vandewalle, Veerle
AU  - Rizos, Alexandra
AU  - Loehrer, Philipp A.
AU  - Silverdale, Monty
AU  - Evans, Julian
AU  - Samuel, Michael
AU  - Petry-Schmelzer, Jan Niklas
AU  - Sauerbier, Anna
AU  - Gronostay, Alexandra
AU  - Barbe, Michael T.
AU  - Fink, Gereon Rudolf
AU  - Ashkan, Keyoumars
AU  - Antonini, Angelo
AU  - Martinez-Martin, Pablo
AU  - Chaudhuri, K. Ray
AU  - Timmermann, Lars
AU  - Dafsari, Haidar S.
AU  - Bhidayasiri, Roongroj
AU  - Falup-Pecurariu, Cristian
AU  - Jeon, Beomseok
AU  - Leta, Valentina
AU  - Borghammer, Per
AU  - Odin, Per
AU  - Schrag, Anette
AU  - Storch, Alexander
AU  - Violante, Mayela Rodriguez
AU  - Weintraub, Daniel
AU  - Adler, Charles
AU  - Barone, Paolo
AU  - Brooks, David J.
AU  - Brown, Richard
AU  - Cantillon, Marc
AU  - Carroll, Camille
AU  - Coelho, Miguel
AU  - Henriksen, Tove
AU  - Hu, Michele
AU  - Jenner, Peter
AU  - Kramberger, Milica
AU  - Kumar, Padma
AU  - Kurtis, Mónica
AU  - Lewis, Simon
AU  - Litvan, Irene
AU  - Lyons, Kelly
AU  - Martino, Davide
AU  - Masellis, Mario
AU  - Mochizuki, Hideki
AU  - Morley, James F.
AU  - Nirenberg, Melissa
AU  - Pagonabarraga, Javier
AU  - Panicker, Jalesh
AU  - Pavese, Nicola
AU  - Pekkonen, Eero
AU  - Postuma, Ron
AU  - Rosales, Raymond
AU  - Schapira, Anthony
AU  - Simuni, Tanya
AU  - Stocchi, Fabrizio
AU  - Subramanian, Indu
AU  - Tagliati, Michele
AU  - Tinazzi, Michele
AU  - Toledo, Jon
AU  - Tsuboi, Yoshio
AU  - Walker, Richard
TI  - Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
JO  - npj Parkinson's Disease
VL  - 7
IS  - 1
SN  - 2373-8057
CY  - London [u.a.]
PB  - Nature Publ. Group
M1  - FZJ-2021-02551
SP  - 48
PY  - 2021
AB  - To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.
LB  - PUB:(DE-HGF)16
C6  - 34103534
UR  - <Go to ISI:>//WOS:000659233200001
DO  - DOI:10.1038/s41531-021-00174-x
UR  - https://juser.fz-juelich.de/record/893091
ER  -